CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
estrogen +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00000482
NCT00000482Phase 3Completed

Coronary Drug Project

National Heart, Lung, and Blood Institute (NHLBI)·interventional·Posted Oct 28, 1999·Updated Nov 26, 2013

In Brief

A Phase 3 clinical trial evaluating estrogen, clofibrate clofibrate, and 2 other interventions for Cardiovascular Diseases and 4 related conditions. Completed.

Detailed Summary

To determine whether regular administration of lipid modifying drugs (clofibrate, nicotinic acid, estrogen, dextrothyroxine) to men with a documented myocardial infarction would result in significant reduction in total mortality over a five year period. Secondarily, to determine whether the degree to which these drugs changed serum lipids was correlated with any effect on mortality and morbidity rates; to gain further information on the long-term prognosis of myocardial infarction (by studying the control group as intensively as the treatment group); to acquire further experience and knowledge concerning the techniques and methodology of long-term clinical trials; to determine, in a substudy, the effectiveness of aspirin, a platelet inhibitor, in reducing recurrences of myocardial infarction.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
19641965196619671968196919701971197219731974197519761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
First PostedOct 28, 1999
Enrollment StartApr 1, 1965
Study CompletionMar 1, 1985
TodayJul 2, 2026
Posted 26.7 years ago

Interventions

estrogendrug

clofibrate clofibratedrug

dextrothyroxine sodiumdrug

niacindrug